Lastly, monocytic DCs (moDCs) were assessed because their role in cancer immunotherapy remains context-dependent and extent of inflammation-dependent and can range from the activation of CD8+ T cells and the induction of a Th1-biased CD4+ T-helper cell responses to their promotion of Treg cell proliferation [20]. This evidence concerns the gene CD4 and cancer.